Search

Your search keyword '"Margherita Di Gaetano"' showing total 3 results
Start Over Author "Margherita Di Gaetano" Topic business
3 results on '"Margherita Di Gaetano"'

1. Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator

Author

Cristina Mussini, Alessandro Cozzi-Lepri, Marianna Menozzi, Marianna Meschiari, Erica Franceschini, Carlotta Rogati, Gianluca Cuomo, Andrea Bedini, Vittorio Iadisernia, Sara Volpi, Jovana Milic, Roberto Tonelli, Lucio Brugioni, Antonello Pietrangelo, Massimo Girardis, Andrea Cossarizza, Enrico Clini, Giovanni Guaraldi, Erica Bacca, Vanni Borghi, Giulia Burastero, Federica Carli, Giacomo Ciusa, Luca Corradi, Margherita Di Gaetano, Matteo Faltoni, Giacomo Franceschi, Gabriella Orlando, Francesco Pellegrino, Cinzia Puzzolante, Alessandro Raimondi, Antonella Santoro, Marco Tutone, Dina Yaacoub, Alberto Andreotti, Emanuela Biagioni, Filippo Bondi, Stefano Busani, Giovanni Chierego, Marzia Scotti, Lucia Serio, Caterina Bellinazzi, Rebecca Borella, Sara De Biasi, Anna De Gaetano, Lucia Fidanza, Lara Gibellini, Anna Iannone, Domenico Lo Tartaro, Marco Mattioli, Annamaria Paolini, Rossella Fogliani, Grazia Righini, and Mario Lugli

Subjects
Male, sex differences, 0301 basic medicine, Microbiology (medical), Mediation (statistics), medicine.medical_specialty, medicine.medical_treatment, 030106 microbiology, Context (language use), Pathogenesis, Cohort Studies, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, Risk Factors, Internal medicine, Humans, Medicine, 030212 general & internal medicine, Respiratory system, female sex, Survival analysis, Aged, Retrospective Studies, Inflammation, Mechanical ventilation, SARS-CoV-2, business.industry, Absolute risk reduction, COVID-19, General Medicine, Middle Aged, Prognosis, medicine.disease, Respiration, Artificial, Hospitalization, Pneumonia, Infectious Diseases, SARS-CoV-2, COVID-19, female sex, prognosis, inflammation, inflammation, Commentary, Female, prognosis, CRP, business, Cohort study
Abstract

Objectives Sex differences in COVID-19 severity and mortality have been described. Key aims of this analysis were to compare the risk of invasive mechanical ventilation (IMV) and mortality by sex and to explore whether variation in specific biomarkers could mediate this difference. Methods This was a retrospective, observational cohort study among patients with severe COVID-19 pneumonia. A survival analysis was conducted to compare time to the composite endpoint of IMV or death by sex. Interaction was formally tested to compare the risk difference by sex in subsets. Mediation analysis with a binary endpoint IMV or death (yes/no) by end of follow-up for a number of inflammation/coagulation biomarkers in the context of counterfactual prediction was also conducted. Results Among 415 patients, 134 were females (32%) and 281 males (67%), median age 66 years (IQR 54-77). At admission, females showed a significantly less severe clinical and respiratory profiles with a higher PaO2/FiO2 (254 mmHg vs 191 mmHg; p=0.023). By 28 days from admission, 49.2% (95% CI: 39.6-58.9%) of males vs. 31.7% (17.9-45.4%) of females underwent IMV or death (log-rank p-value Conclusions Our analysis confirms a difference in the risk of COVID-19 clinical progression by sex and provides a hypothesis for potential mechanisms leading to this. CRP showed a predominant role to mediate the difference in risk by sex.

Published
2021

2. COVID-19-associated vasculitis and thrombotic complications: from pathological findings to multidisciplinary discussion

Author

Maria Teresa Mascia, Gianrocco Manco, Gaetano Alfano, Andrea Cossarizza, Giacomo Ciusa, Nicola De Ruvo, Ivana Castaniere, Marianna Meschiari, Roberto Tonelli, Erica Franceschini, Marco Tutone, Gabriella Orlando, Cristina Mussini, Federica Carli, Marianna Menozzi, Marco Marietta, Antonella Santoro, Erica Bacca, Antonino Maiorana, Matteo Faltoni, Roberta Gelmini, Caterina Vacchi, Giovanni Rolando, Giovanni Guaraldi, Carlo Salvarani, Cinzia Puzzolante, Sara Volpi, Margherita Di Gaetano, Giacomo Franceschi, Massimo Girardis, Guido Ligabue, Gianluca Cuomo, Andrea Bedini, Jovana Milic, and Alessandro Raimondi

Subjects
Vasculitis, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, SARS-CoV-2, Ischemia, MEDLINE, COVID-19, medicine.disease, Letter to the Editor (Case report), Rheumatology, Multidisciplinary approach, Pandemic, Medicine, Humans, Pharmacology (medical), business, Intensive care medicine, Pathological, Pandemics, AcademicSubjects/MED00360, Thrombotic complication
Published
2020

3. Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Author

Ivana Castaniere, Jovana Milic, Marianna Menozzi, Maddalena Giannella, Marianna Meschiari, Lucio Brugioni, Alessandro Cozzi-Lepri, Massimo Girardis, Cinzia Puzzolante, Enrico Clini, Margherita Di Gaetano, Vanni Borghi, Sara K. Tedeschi, Erica Franceschini, Michele Bartoletti, Gabriella Orlando, Luca Tabbì, Antonella Santoro, Andrea Bedini, Carlo Salvarani, Federica Carli, Federico Pea, Antonello Pietrangelo, Luca Corradi, Gianluca Cuomo, Roberto Tonelli, Pierluigi Viale, Riccardo Fantini, Andrea Cossarizza, Giovanni Guaraldi, Renato Pascale, Cristina Mussini, Marco Massari, Giovanni Dolci, Guaraldi G., Meschiari M., Cozzi-Lepri A., Milic J., Tonelli R., Menozzi M., Franceschini E., Cuomo G., Orlando G., Borghi V., Santoro A., Di Gaetano M., Puzzolante C., Carli F., Bedini A., Corradi L., Fantini R., Castaniere I., Tabbi L., Girardis M., Tedeschi S., Giannella M., Bartoletti M., Pascale R., Dolci G., Brugioni L., Pietrangelo A., Cossarizza A., Pea F., Clini E., Salvarani C., Massari M., Viale P.L., and Mussini C.

Subjects
Mechanical ventilation, medicine.medical_specialty, medicine.drug_class, business.industry, medicine.medical_treatment, Immunology, Low molecular weight heparin, Retrospective cohort study, Azithromycin, medicine.disease, Article, chemistry.chemical_compound, Pneumonia, Tocilizumab, chemistry, Rheumatology, Internal medicine, severe covid-19, tocilizumab, medicine, Clinical endpoint, Immunology and Allergy, business, Letters to the Editor, Cohort study, medicine.drug
Abstract

Background: No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment. Methods: This retrospective, observational cohort study included adults (≥18 years) with severe COVID-19 pneumonia who were admitted to tertiary care centres in Bologna and Reggio Emilia, Italy, between Feb 21 and March 24, 2020, and a tertiary care centre in Modena, Italy, between Feb 21 and April 30, 2020. All patients were treated with the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin), and a non-randomly selected subset of patients also received tocilizumab. Tocilizumab was given either intravenously at 8 mg/kg bodyweight (up to a maximum of 800 mg) in two infusions, 12 h apart, or subcutaneously at 162 mg administered in two simultaneous doses, one in each thigh (ie, 324 mg in total), when the intravenous formulation was unavailable. The primary endpoint was a composite of invasive mechanical ventilation or death. Treatment groups were compared using Kaplan-Meier curves and Cox regression analysis after adjusting for sex, age, recruiting centre, duration of symptoms, and baseline Sequential Organ Failure Assessment (SOFA) score. Findings: Of 1351 patients admitted, 544 (40%) had severe COVID-19 pneumonia and were included in the study. 57 (16%) of 365 patients in the standard care group needed mechanical ventilation, compared with 33 (18%) of 179 patients treated with tocilizumab (p=0·41; 16 [18%] of 88 patients treated intravenously and 17 [19%] of 91 patients treated subcutaneously). 73 (20%) patients in the standard care group died, compared with 13 (7%; p

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results